Semaglutide vs Saxenda: When Daily Injections Make Sense

Saxenda (liraglutide) is the older drug, the daily injection, and by most efficacy measures the weaker option. Wegovy (semaglutide) is the weekly injection, the newer molecule, and the one that produces meaningfully better weight loss in head-to-head comparisons. So why would anyone choose Saxenda in 2024 and beyond?

The answer is narrower than it used to be — but it's real. Two situations in particular make liraglutide vs semaglutide a genuine conversation rather than an automatic answer: pregnancy planning and insurance coverage gaps. A third is tolerability. If you're in one of these situations, the weekly/daily distinction matters more than the efficacy gap.

Efficacy: The Honest Comparison

Starting with the numbers, because they frame everything else.

The major weight-loss trials:

The gap is significant — roughly 6–7 percentage points — and it's not primarily explained by duration or population differences. Semaglutide simply produces more weight loss than liraglutide at their respective approved doses.

Direct head-to-head data: the STEP-8 trial (Rubino et al., 2022, JAMA) compared semaglutide 2.4 mg weekly vs. liraglutide 3 mg daily in people with obesity. Semaglutide produced 15.8% weight loss vs. liraglutide's 6.4% over 68 weeks — a 9.4 percentage point difference. Semaglutide also had numerically better tolerability in this comparison, with fewer GI-related discontinuations.

If your only goal is maximum weight loss and both drugs are equally accessible, the data clearly favors semaglutide. That's not in dispute. The question is when circumstances shift the calculation.

The Washout Advantage: Why Pregnancy Planners Notice

This is the most pharmacologically interesting reason to choose Saxenda.

Liraglutide (Saxenda) has a half-life of approximately 12–13 hours. After stopping, it clears the system in roughly 2–3 days. At that point, from a pharmacological standpoint, the drug is gone.

Semaglutide (Wegovy/Ozempic) has a half-life of approximately 7 days. After stopping, complete clearance takes roughly 5 weeks (about 5 half-lives). Current FDA guidance for Wegovy recommends stopping at least 2 months before a planned pregnancy to allow adequate washout time.

GLP-1 drugs are not recommended during pregnancy — animal studies have shown fetal growth effects, and there's insufficient human safety data to change that guidance. For someone on semaglutide who decides to start trying to conceive, that means a 2-month pharmacological waiting period after stopping the drug.

For someone on liraglutide, that window is essentially 3–5 days.

For couples on a specific conception timeline — particularly those using assisted reproduction (IUI, IVF cycles), where timing is scheduled to the day — the difference between a 2-day washout and an 8-week washout can mean one or two additional treatment cycles. That's not a trivial difference.

Some clinicians are now specifically prescribing Saxenda rather than Wegovy for patients who are 6–12 months from a planned pregnancy attempt, with the plan to switch back to semaglutide post-partum if desired.

Insurance Edge Cases

The insurance landscape for GLP-1 drugs varies widely and changes frequently, but Saxenda vs Wegovy formulary differences are a legitimate reason to look at liraglutide for some people.

A few scenarios where Saxenda has or has had a coverage edge:

Older commercial formularies. Saxenda has been on the market since 2014 and is covered by some plans that haven't yet added Wegovy. If your employer plan has Saxenda on formulary as a Tier 2 and Wegovy as Tier 4 (or uncovered), the out-of-pocket difference can be thousands of dollars per year.

State Medicaid programs. Coverage for Wegovy under Medicaid varies by state and has been expanded and restricted in different cycles. Saxenda's longer track record has led to more consistent coverage on some state formularies.

Prior authorization pathways. Some plans have more established PA pathways for Saxenda — meaning less hassle even if both are technically covered.

The landscape shifts regularly, and it's always worth checking your specific formulary before assuming semaglutide is the easier or cheaper path. Your pharmacy benefits manager or a GLP-1-specialized telehealth platform can usually give you the current picture quickly.

Tolerability Differences

The daily vs weekly GLP-1 distinction affects the tolerability profile in a specific way.

With semaglutide (weekly), you get one dose per week and one peak of potential GI side effects — usually the 24–72 hours after injection. For most people, this means a rough patch once a week that fades by days 4–7.

With liraglutide (daily), you get lower peaks with more constant trough levels. Some people find the steady-state pharmacokinetics more tolerable than the weekly bolus effect of semaglutide — particularly those who experience pronounced nausea in the 1–2 days after each semaglutide dose.

That said, the majority of people find semaglutide's tolerability acceptable once they're past the titration period, and the STEP-8 head-to-head actually showed fewer GI discontinuations with semaglutide vs. liraglutide.

For a minority of patients — usually those who've tried semaglutide and found the weekly cycle of nausea difficult to manage — the daily, lower-peak profile of liraglutide may work better even at the cost of less weight loss.

Who Uses Saxenda Today

Given all of the above, the current realistic use cases for Saxenda in someone who has access to both drugs:

1. Pregnancy planning within 12 months. The washout advantage is real and clinically meaningful. Saxenda is a reasonable bridge option for someone who wants pharmacological support for 6–12 more months before coming off GLP-1 therapy entirely.

2. Insurance gap. If Saxenda is covered and Wegovy is not, or if the out-of-pocket difference is substantial, Saxenda at 8.4% mean weight loss is still meaningfully better than no pharmacological support.

3. Cycle tolerability preference. A small number of patients who've tried both genuinely prefer the smoother daily pharmacokinetics. This is person-dependent and not predictable in advance.

What Saxenda is not, for most people in most situations: the better drug. The efficacy gap in STEP-8 is large enough that it takes a specific circumstance to justify the trade. But the circumstances are specific, not rare.

Switching Between the Two

Moving from Saxenda to semaglutide: standard guidance is to stop liraglutide and begin semaglutide at the titration starting dose (0.25 mg weekly), even if you were at a high liraglutide dose. There's no formal cross-titration guidance, but most clinicians don't continue at a higher semaglutide dose on day 1. The rationale is that GLP-1 receptor sensitivity can vary, and starting low reduces the risk of a bad GI event on transition.

Moving from semaglutide to Saxenda: less common, but the same principle applies. Start liraglutide at 0.6 mg and titrate up per the standard schedule. Given semaglutide's long half-life, the transition period involves overlapping drug levels for several weeks — which doesn't create dangerous interactions but does mean you're not completely drug-free between the two.

For the full semaglutide dosing and titration picture, see semaglutide dosing schedule. For context on compounded semaglutide and what to expect on both drugs, the semaglutide pillar page covers the full landscape.

Related reading

• Semaglutide: the complete guide
• Semaglutide dosing schedule
• Stopping semaglutide: what the data says
• Tirzepatide vs semaglutide